MUSK and myasthenia gravis: In a prospective open label study on a cohort of MuSK Ab+ MG patients who were followed up for a median duration of 3.5 years, 58% of patients who received rituximab vs. 16% of those who did not had a favorable clinical outcome and lower doses of immunosuppressants [143].